Neurocrine Biosciences (NBIX) closed at $135.71 on Oct 16, 2026, down 0.9% on the day. The stock is down 10.6% over the past month, down 21.6% over three months, down 4.3% year to date and down 1.5% over the past year. It trades 27.1% below its 52-week high of $186.12 and 11.1% above its 52-week low of $122.14. The close sits below its 50-day moving average ($149.26) and below its 200-day moving average ($147.05).
NextPick tracks NBIX in its Biotech basket alongside VRTX, MRNA, REGN, BIIB and ALNY. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month NBIX ranks 10th of 17 basket members by price change.
NBIX is scheduled to report earnings on Nov 2, 2026.
Neurocrine Biosciences is scheduled to report on Nov 2, 2026.
No — the Oct 16, 2026 close of $135.71 is 7.7% below the 200-day average of $147.05.
NBIX closed 27.1% below its 52-week high of $186.12.
NextPick groups NBIX with VRTX, MRNA, REGN, BIIB and ALNY in its Biotech basket.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
